Ascento-CDA

Company Overview

Snapshot

Founded in December 2024 by Marvin Collin, Rami Cohen, and Raphael Nir, Ascento-CDA operates with 1–10 employees. The company has raised $350,000 across one funding round. In October 2025, Ascento-CDA published research on the early identification of cognitive decline disease promoters, highlighting its scientific validation efforts.

Business overview

Ascento-CDA is a healthcare analytics company focused on the early detection of dementia and diabetes. The company develops a proprietary analytic engine that integrates immunology data, retinal imaging signals, and cognitive assessments to identify early biologic activity years before symptoms manifest. This platform transforms existing clinical data into actionable intelligence, reclassifying hidden risk in patients to enable earlier, more targeted interventions. Ascento-CDA serves insurers, payers, and health providers, aiming to reduce lifetime medical costs for the former and unlock new revenue streams for the latter through expanded outpatient utilization. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, leveraging artificial intelligence and machine learning.

Strategic signal

In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using its Inflammatory, Immunologic, and Cognitive Mapping (IICM™) approach. This publication signals significant progress in validating the company's core technology and its potential to revolutionize early disease detection. For investors, this demonstrates Ascento-CDA's commitment to scientific rigor and provides crucial evidence of its platform's efficacy, positioning it as a credible innovator in the health tech space focused on high-impact, long-duration healthcare cost drivers.

Company Intelligence Q&A

What is Ascento-CDA's core mission?

Ascento-CDA is dedicated to the early detection of dementia and diabetes by identifying biologic activity years before symptoms appear, aiming to address major cost drivers in global healthcare.

What technology does Ascento-CDA utilize for early disease detection?

Ascento-CDA employs a proprietary analytic engine that integrates immunology data, retinal imaging signals, and cognitive assessments to surface early biologic activity that conventional tools often miss.

What was the significance of Ascento-CDA's publication in October 2025?

In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using its Inflammatory, Immunologic, and Cognitive Mapping (IICM™) method, validating its approach to early disease detection.

Which markets does Ascento-CDA target with its platform?

Ascento-CDA targets both sides of the healthcare market, providing value to insurers and payers through cost reduction and to health providers through new revenue generation from earlier diagnostics and care programs.

What is Ascento-CDA's current funding status?

Ascento-CDA has raised a total of $350,000 in a Seed funding round in January 2025. The specific investors for this round have not been disclosed.